
NanoPhoria Bioscience is a preclinical-stage biotech with proprietary Nano-in-Micro delivery technology built on inorganic Calcium Phosphate (CaP) nanoparticles.
nanophoria.comCrawled Nov 5, 2026
NanoPhoria combines cardiovascular biology and materials science to create its evidence-based therapeutic platform.
NanoPhoria’s lead asset is NP-MP1, an investigational therapy for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF).
NanoPhoria’s delivery platform uses inorganic Calcium Phosphate nanoparticles to carry or decorate biologics.
European Biotechnology 2026 European Start-ups to Watch
NanoPhoria was selected to receive financial support in a highly competitive European Innovation Council (EIC) Accelerator funding round with over 1200 applications.
NanoPhoria is a biotech company advancing inhaled cardiovascular treatments using a Nano-in-Micro delivery platform for peptides and RNAs.
NanoPhoria is backed by multiple leading investment groups, and most recently closed a €83.5 Million Series A round led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital.
NanoPhoria invites inquiries about partnerships, NP-MP1, its delivery platform, and cardiovascular research collaborations.
NanoPhoria Bioscience is a preclinical-stage biotechnology company
NanoPhoria Bioscience completes a €15 million equity investment from the European Innovation Council (EIC) Fund as part of its Series A financing round. The funding marks a record for Italian biotech financing rounds. The company focuses on developing advanced biopharmaceutical solutions.
Jan 2026Drug Discovery World (DDW)News article
NanoPhoria Bioscience raises €83.5 million in Series A funding to advance its heart failure therapy. The round includes participation from XGEN Venture, Sofinnova Partners, CDP Venture Capital, and Panakès Partners. The company, based in Milan, focuses on biotech innovations targeting cardiovascular treatments.
Oct 2025Pulse 2.0News article
NanoPhoria Bioscience raises €83.5 million in Series A funding to develop a novel therapy for heart failure. The Milan-based biotech firm completes the first close of its funding round, accelerating its pipeline of innovative treatments. The capital will support clinical development and research for its heart failure solutions.
Oct 2025Pharma JournalistNews article
NanoPhoria secures €83.5 million in financing to advance **NP-MP1**, an inhaled dry powder peptide therapy targeting heart failure. The funds will support clinical development and manufacturing of the novel treatment, which delivers peptides via a dry powder formulation for respiratory administration. The company focuses on peptide-based solutions for cardiovascular diseases, leveraging its expertise in inhaled drug delivery systems.
Oct 2025oindpnews.comNews article